Unresectable Hepatocellular Carcinoma Recruiting Phase 1 / 2 Trials for Nivolumab (DB09035)

IndicationStatusPhase
DBCOND0033719 (Unresectable Hepatocellular Carcinoma)Recruiting1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03695250BMS-986205 and Nivolumab as First Line Therapy in Treating Patients With Liver CancerTreatment